Literature DB >> 12734353

TNF enhances CD4+ T cell alloproliferation, IFN-gamma responses, and intestinal graft-versus-host disease by IL-12-independent mechanisms.

Geri R Brown1, Edward L Lee, Dwain L Thiele.   

Abstract

Inhibition of TNF/TNFR2 interactions ameliorates intestinal graft-vs-host disease (GVHD) and Th1 cytokine responses induced by transfer of B6 CD4(+) spleen cells into irradiated MHC class II disparate B6.C-H-2(bm12) (bm12) x B6 F(1) recipients. The present studies examined whether these effects of TNF are IL-12 dependent. T cell proliferative responses of B6.129S1-IL-12rb2(tm1Jm) (B6.IL-12R(-/-)) responder spleen cells were found to be comparable to those of control B6 spleen cells. TNF inhibition reduced T cell proliferation and IFN-gamma production in supernatants of MLC using either B6.IL-12R(-/-) or control B6 responder cells. GVHD induced wasting disease in recipients of B6.IL-12R(-/-) CD4(+) spleen cells that received a TNF inhibitor-encoding adenovirus (5.4 +/- 6.5% weight loss (n = 7)) was significantly reduced compared with levels of weight loss observed in recipients that had received a control adenovirus (25.7 +/- 12.2% weight loss (n = 11), p = 0.001). Furthermore, TNF inhibition was associated with a reduction in colonic GVHD scores (p = 0.039) and in the percentage of the splenic CD4(+) T cells that expressed IFN-gamma (16 vs 6%). These findings indicate that TNF promotes CD4(+) T cell alloproliferation, IFN-gamma responses, and intestinal GVHD by IL-12-independent mechanisms.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12734353     DOI: 10.4049/jimmunol.170.10.5082

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  10 in total

1.  IL-6 and TNF-alpha synergistically inhibit allograft acceptance.

Authors:  Hua Shen; Daniel R Goldstein
Journal:  J Am Soc Nephrol       Date:  2009-04-08       Impact factor: 10.121

2.  T cells require tumor necrosis factor-alpha to provide protective immunity in mice infected with Histoplasma capsulatum.

Authors:  George S Deepe; Reta S Gibbons
Journal:  J Infect Dis       Date:  2005-12-05       Impact factor: 5.226

3.  Pre-clinical screening of immunomodulatory compounds using the parent-into-F1 model.

Authors:  Charles S Via
Journal:  Clin Immunol       Date:  2011-06-12       Impact factor: 3.969

4.  Indirect regulation of CD4 T-cell responses by tumor necrosis factor receptors in an acute viral infection.

Authors:  Anju Singh; Marcel Wüthrich; Bruce Klein; M Suresh
Journal:  J Virol       Date:  2007-04-04       Impact factor: 5.103

5.  Donor CD8 T cells and IFN-gamma are critical for sex-based differences in donor CD4 T cell engraftment and lupus-like phenotype in short-term chronic graft-versus-host disease mice.

Authors:  Anthony D Foster; Kateryna Soloviova; Irina Puliaeva; Maksym Puliaiev; Roman Puliaev; Fred Finkelman; Charles S Via
Journal:  J Immunol       Date:  2011-04-29       Impact factor: 5.422

6.  CD8 T cells regulate allergic contact dermatitis by modulating CCR2-dependent TNF/iNOS-expressing Ly6C+ CD11b+ monocytic cells.

Authors:  Shu Zhen Chong; Kar Wai Tan; Fiona H S Wong; Yen Leong Chua; Yafang Tang; Lai Guan Ng; Veronique Angeli; David M Kemeny
Journal:  J Invest Dermatol       Date:  2013-09-23       Impact factor: 8.551

7.  Etanercept plus methylprednisolone as initial therapy for acute graft-versus-host disease.

Authors:  John E Levine; Sophie Paczesny; Shin Mineishi; Thomas Braun; Sung W Choi; Raymond J Hutchinson; Dawn Jones; Yasser Khaled; Carrie L Kitko; Daniel Bickley; Oleg Krijanovski; Pavan Reddy; Gregory Yanik; James L M Ferrara
Journal:  Blood       Date:  2007-11-27       Impact factor: 22.113

8.  Spatiotemporal single-cell profiling reveals that invasive and tissue-resident memory donor CD8+ T cells drive gastrointestinal acute graft-versus-host disease.

Authors:  Victor Tkachev; James Kaminski; E Lake Potter; Scott N Furlan; Alison Yu; Daniel J Hunt; Connor McGuckin; Hengqi Zheng; Lucrezia Colonna; Ulrike Gerdemann; Judith Carlson; Michelle Hoffman; Joe Olvera; Chris English; Audrey Baldessari; Angela Panoskaltsis-Mortari; Benjamin Watkins; Muna Qayed; Yvonne Suessmuth; Kayla Betz; Brandi Bratrude; Amelia Langston; John T Horan; Jose Ordovas-Montanes; Alex K Shalek; Bruce R Blazar; Mario Roederer; Leslie S Kean
Journal:  Sci Transl Med       Date:  2021-01-13       Impact factor: 19.319

Review 9.  Targeting inflammation and immune activation to improve CTLA4-Ig-based modulation of transplant rejection.

Authors:  Marcos Iglesias; Daniel C Brennan; Christian P Larsen; Giorgio Raimondi
Journal:  Front Immunol       Date:  2022-09-02       Impact factor: 8.786

10.  Human peripheral blood leucocyte non-obese diabetic-severe combined immunodeficiency interleukin-2 receptor gamma chain gene mouse model of xenogeneic graft-versus-host-like disease and the role of host major histocompatibility complex.

Authors:  M A King; L Covassin; M A Brehm; W Racki; T Pearson; J Leif; J Laning; W Fodor; O Foreman; L Burzenski; T H Chase; B Gott; A A Rossini; R Bortell; L D Shultz; D L Greiner
Journal:  Clin Exp Immunol       Date:  2009-07       Impact factor: 4.330

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.